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Average bioequivalence of two 500 mg levofloxacin formulations available in Brazil, Tavanic© (Sanofi-
Aventis Farmacêutica Ltda, Brazil, reference product) and Levaquin© (Janssen-Cilag Farmacêutica 
Ltda, Brazil, test product) was evaluated by means of a randomized, open-label, 2-way crossover 
study performed in 26 healthy Brazilian volunteers under fasting conditions. A single dose of 500 mg 
levofloxacin tablets was orally administered, and blood samples were collected over a period of 48 hours. 
Levofloxacin plasmatic concentrations were determined using a validated HPLC method. Pharmacokinetic 
parameters Cmax, Tmax, Kel, T1/2el, AUC0-t and AUC0-inf were calculated using noncompartmental analysis. 
Bioequivalence was determined by calculating 90% confidence intervals (90% CI) for the ratio of Cmax, 
AUC0-t and AUC0-inf values for test and reference products, using logarithmic transformed data. Tolerability 
was assessed by monitoring vital signs and laboratory analysis results, by subject interviews and by 
spontaneous report of adverse events. 90% CIs for Cmax, AUC0–t and AUC0-inf were 92.1% - 108.2%, 
90.7% - 98.0%, and 94.8% - 100.0%, respectively. Observed adverse events were nausea and headache. 
It was concluded that Tavanic© and Levaquin© are bioequivalent, since 90% CIs are within the 80% - 
125% interval proposed by regulatory agencies.
Uniterms: Levofloxacin/bioequivalence. Pharmacokinetics. High-performance liquid chromatography/
qualitative analysis. Tavanic©/bioequivalence. Levaquin©/bioequivalence.
A bioequivalência média de duas formulações de levofloxacino disponíveis no Brasil, Tavanic© (Sanofi-
Aventis Farmacêutica Ltda, Brasil, produto referência) e Levaquin© (Janssen-Cilag Farmacêutica Ltda, 
Brasil, produto teste) foi determinada por meio da realização de ensaio aleatório, aberto, cruzado, com 
dois períodos e duas sequências, em 26 voluntários sadios em condições de jejum. Amostras de sangue 
dos voluntários foram obtidas ao longo de um período de 48 horas após administração de dose única 
de 500 mg de levofloxacino. As concentrações plasmáticas do fármaco foram determinadas por método 
cromatográfico validado. Os parâmetros farmacocinéticos Cmax, Tmax, Kel, T1/2el, AUC0-t e AUC0-inf foram 
calculados por análise não compartimental. A bioequivalência foi determinada pelo cálculo de intervalos 
de confiança 90% (IC 90%) para as razões entre os valores de Cmax, AUC0-t e AUC0-inf obtidos para os 
produtos teste e referência, usando dados transformados logaritmicamente. A tolerabilidade foi avaliada 
pelo acompanhamento dos sinais vitais e resultados de exames laboratoriais, por consultas e por relato 
espontâneo dos voluntários. ICs 90% para Cmax, AUC0–t e AUC0-inf foram 92.1% - 108.2%, 90.7% - 98.0%, 
e 94.8% - 100.0%, respectivamente. Os eventos adversos observados foram náusea e cefaleia. Concluiu-
se que os produtos Tavanic© e Levaquin© são bioequivalentes, uma vez que os ICs 90% estão dentro da 
faixa de 80%-125% proposta pelas agências reguladoras.
Unitermos: Levofloxacino/bioequivalência. Farmacocinética. Cromatografia líquida de alta eficiência/
análise qualitativa. Tavanic©/bioequivalência. Levaquin©/bioequivalência.
E. K. Kano, E. E. M. Koono, S. G. Schramm, C. H. R. Serra, E. Abib Junior, R. Pereira, M. S. T. Freitas, M. C. Iecco, V. Porta204
INTRODUCTION
Levofloxacin is the synthetic L-isomer of the 
racemic quinolone ofloxacin (Anderson, Perry, 2008; 
Siewert, 2006). The drug is administered to treat infectious 
diseases, e.g. community acquired and nosocomial 
pneumonia, skin and skin structure infections and 
urinary tract infections (Siewert, 2006). It has a broad 
spectrum antibacterial profile including Gram-positive as 
well as Gram-negative bacteria, and atypical organisms 
(Anderson, Perry, 2008; Croom, Goa, 2003; Noreddin, 
Haynes, Zhanel, 2005; Takahashi, Hayakawa, Akimoto, 
2003). Levofloxacin is well tolerated, and is associated 
with few of the phototoxic, cardiac or hepatic adverse 
events seen with some other quinolones. Adverse events 
occurring in ≥2% of patients receiving once-daily 
levofloxacin 750 mg for 5 days or once-daily levofloxacin 
500 mg for 10 days are nausea, headache, diarrhea, 
insomnia, constipation, abdominal pain, dizziness, 
dyspepsia and vomiting. Rare adverse effects associated 
with levofloxacin include photosensitivity/phototoxicity 
reactions after exposure to the sun or ultraviolet (UV) light, 
C. difficile diarrhoea which may vary in severity from mild 
to fatal colitis, tendon ruptures, sensory or sensorimotor 
axonal poly-neuropathy, and hypersensitivity (Anderson, 
Perry, 2008; Croom, Goa, 2003).
Oral levofloxacin undergoes complete absorption, 
and the time to maximum concentration (Tmax) occurs 1-2 
hours after a 500 or 750 mg oral dose, in subjects with 
normal renal function. The absolute bioavailability is 99% 
or greater and the oral solution or tablet formulation have 
the same bioavailability as the intravenous formulation 
(Anderson, Perry, 2008). Levofloxacin serum half-life 
is 6-7 hours (Lee et al., 1997; Lubasch et al., 2000; 
Wagenlehner et al., 2006). It has a large volume of 
distribution allowing for penetration in various cells 
and tissues, including alveolar cells or macrophages 
and paranasal sinuses mucosa, where it can achieve 
concentrations that surpass plasma levels after 2-4 hours 
of administration (Anderson, Perry, 2008; Croom, Goa, 
2003). Pharmacokinetics of levofloxacin is not affected by 
age, gender, race, HIV (human immunodeficiency virus) 
status or the presence of serious community-acquired 
bacterial infections (Anderson, Perry, 2008). However, 
Tmax and maximum plasma concentration (Cmax) were 
affected by consumption of a high-fat meal, although 
the extent of absorption was not affected (Rodvold, 
Neuhauser, 2001). Because renal clearance accounts 
for most of total body clearance of levofloxacin, its 
pharmacokinetics is affected by renal impairment but 
not by hepatic impairment (Rodvold, Neuhauser, 2001). 
Levofloxacin and newer quinolones, when compared with 
older agents such as ciprofloxacin, achieve higher peak 
serum concentrations (Cmax), resulting in higher Cmax/MIC 
(minimum inhibitory concentration) ratios, which result 
in excellent bacterial killing (Noreddin, Haynes, Zhanel, 
2005).
The bioavailability of a drug product is defined 
as the rate and extent to which the active ingredient or 
therapeutic moiety is absorbed and becomes available at 
the site of drug action. Two drug products are considered 
to be bioequivalent if they are pharmaceutical equivalents 
(i.e., similar dosage forms made, perhaps, by different 
manufacturers) or pharmaceutical alternatives (i.e., different 
dosage forms) and if their rates and extents of absorption 
do not show a significant difference when administered at 
the same molar dose of the therapeutic moiety under similar 
experimental conditions (Chow, Liu, 2000).
Bioavailability and bioequivalence studies provide 
important information in the overall set of data that ensure 
the availability of safe and effective medicines to patients 
and clinicians. These studies gained increasing attention 
during the last decades, after it became evident that 
marketed products having same amounts of the same drug 
may exhibit marked differences between their therapeutic 
responses. In many instances, these differences were 
correlated successfully to dissimilar drug blood levels 
caused mainly by impaired absorption (Abdou, 1989; 
Chen et al., 2001).
According to international criteria (Agência 
Nacional de Vigilância Sanitária, 2006; European 
Medicines Agency, 2010; FDA, 2001),  average 
bioequivalence between two pharmaceutical products is 
determined by comparing its bioavailabilities through the 
assessment of rate and extension of drug absorption and 
through the calculation of 90% confidence intervals (90% 
CI) for the ratio of Cmax, and AUC (area under the plasma 
concentration-time curve) values for both products, using 
logarithmic transformed data. The products are considered 
bioequivalent if all 90% CI fall within 80%-125%.
Especially in antimicrobial therapy, bioequivalence 
studies are very important, since the dosage form must 
provide effective plasma concentration, thereby assuring 
the elimination of the microorganism, which causes the 
infection. Should the plasma concentration fall below the 
level required to ensure efficacy, the infection will not be 
eradicated and the risk of developing resistance to the drug 
may increase (Porta, Chang, Storpirtis, 2005).
Several Brazilian pharmaceutical industries currently 
produce or import levofloxacin tablets formulations. 
These formulations must prove bioequivalence to the 
reference product to be marketed in Brazil. Thus, the aim 
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of the present study was to compare the pharmacokinetic 
profile and to evaluate the bioequivalence of two 500 mg 
levofloxacin formulations available in Brazil, Tavanic© 
(Sanofi-Aventis Farmacêutica Ltda, Brazil, reference 
product) and Levaquin© (Janssen-Cilag Farmacêutica 
Ltda, Brazil, test product) for regulatory approval of 
Levaquin©.
SUBJECTS AND METHODS
Ethics committee review and selection of 
volunteers
The study was carried out in accordance with 
the principles of the Declaration of Helsinki and its 
amendments (World Medical Association, 2008) and the 
International Conference on Harmonization Guideline 
for Good Clinical Practice (International Conference on 
Harmonization, 1996). The protocol was approved by the 
Ethics Committee of the College of Medical Sciences of 
the University of Campinas.
Medical history, physical examination, 12-lead 
electrocardiography, and laboratory tests (hematology, 
blood biochemistry, hepatic function and urinalysis) 
were carried out prior to the beginning of the study and 
at its conclusion. Inclusion criteria were weight within 
15% of ideal body weight, absence of heart, kidneys, 
neurological or metabolic diseases and no history of drug 
hypersensitivity. Exclusion criteria were abnormal values 
on physical examination, eletrocardiography or laboratory 
tests, ongoing pharmacological treatment and pregnancy. 
Volunteers were instructed to abstain from taking any 
medication one week before and during the study.
Study design and drug administration
The bioequivalence of levofloxacin tablet at a single 
dose of 500 mg was assessed under fasting conditions, in 
an open, randomized, 2x2 crossover trial, with a washout 
period of 6 days. Although Tmax and Cmax could be affected 
by consumption of a high-fat meal, effect of food was not 
tested, since it is not required in Brazil for registration of 
immediate release oral formulations.
Subjects were admitted into hospital at 9:00p.m., 
the day before the drug administration and were randomly 
assigned to group A or B. During the first period, 
volunteers from group A received a single 500 mg 
dose of reference product (Tavanic©, Sanofi-Aventis 
Famacêutica Ltda, Brazil), while volunteers from group B 
received a single 500 mg dose of test product (Levaquin©, 
Janssen-Cilag Farmacêutica Ltda, Brazil), according to a 
randomization schedule. In the second study period, the 
order was reversed.
The products were administered in the morning 
with 200 mL of water after a 10 hours fasting period. No 
food was allowed for 4 hours after ingestion of the dose. 
Subjects were provided with standard meals 4 hours 
(lunch), 7 hours (snack) and 10 hours (supper) after drug 
administration in each treatment. Volunteers did not ingest 
any alcoholic drink, coffee or xanthine containing drinks 
or foods during the trial.
Tolerability
Tolerability was assessed by a clinician by 
monitoring vital signs (blood pressure in the upper arm 
using sphygmomanometry, and heart rate) at 1.0, 2.0, 
4.0, 6.0, 8.0, 12.0, 24.0, 36.0 e 48.0 hours after drug 
administration, by interviewing subjects at each sampling 
time and at each meal, and by registering adverse events 
spontaneously reported during the course of the study.
Sample collection and processing
Sample collection was achieved by means of an 
indwelling venous cannula of the cubital vein maintained 
with 1 ml of heparin diluted with normal saline solution to 
a final concentration of 50 mg/L. Eight milliliters of venous 
blood were collected to heparinized tubes according to a 
time schedule which included a blank before-drug sample 
just prior to dosing (predose) and samples at 0.5, 1.0, 1.5, 
2.0, 2.5, 3.0, 3.5, 4.0, 6.0, 8.0, 12.0, 24.0, 36.0 and 48.0 
hours after drug administration. One milliliter of blood 
was collected and discarded before each sample collection. 
Plasma was immediately separated by centrifugation 
at 1900 g for 10 min under refrigeration (4 °C). Plasma 
samples were divided into two aliquots, transferred to 
labeled tubes, and stored at -20 °C until analytic assay.
Analysis of plasma samples
For the determination of levofloxacin plasmatic 
levels, an accurate, precise and sensitive high performance 
liquid chromatography (HPLC) method with UV detection 
was developed and validated, based on previously 
described methods (Almeida et al., 2005; Baietto et 
al., 2009; Chien et al., 1997, 1998; Conte et al., 2006; 
Djabarouti et al., 2004; Ji et al., 2006; Lee et al., 1997; 
Liang, Kays, Sowinski, 2002; Lubasch et al., 2000; 
Nemutlu et al., 2007; Schulte et al., 2006; Siewert, 2006; 
Wagenlehner et al., 2006; Wong, Juzwin, Flor, 1997; Zhou 
et al., 2007).
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Metronidazol was used as internal standard (IS). 
Briefly, 250 µL of plasma and 25 µL of IS solution 
(80 µg/mL) were added to a 8 mL glass test tube and 
vortex-mixed for 30 seconds; after this procedure, a 
2 mL volume of acetonitrile was added for protein 
precipitation. Samples were centrifuged for 10 minutes 
at 1900 g. The supernatant layer was filtered through a 
Millex GV 0.45 µm filter unit into an 8 mL conical glass 
tube and solvent was evaporated under a nitrogen stream 
while immersed in a 40 °C water bath. Each sample was 
reconstituted with 250 µL of mobile phase and vortex-
mixed for 30 seconds. The samples were transferred to 
auto-sampler vials and 25 µL were injected into the HPLC 
system. Chromatographic separation was performed in a 
Gemini C18 column, 150 × 4.6 mm I.D., 5 µm particle 
size (Phenomenex®, Torrance, USA), protected with an 
AJO-4287 C18 guard cartridge, 5 × 4.6 mm I.D., 5 µm 
particle size (Phenomenex®, Torrance, USA). The mobile 
phase consisted of a solution of sodium dihydrogen 
phosphate monohydrate (25 mM) and acetonitrile in 
the ratio of 87:13 (v/v), without pH adjustment, filtered 
through a 0.22 µm filter and ultrasonically degassed for 
15 min. The chromatographic column was maintained 
at 40 °C during the analysis. The mobile phase flow-rate 
was set at 1.2 mL/min and the detection wavelength, at 
280 nm.
Method val ida t ion  was  achieved through 
determination of specificity, recovery, linearity, lower 
limit of quantification (LLOQ), precision, accuracy and 
stability using standard plasma samples (0.25 µg/mL 
to 10.00 µg/mL) and quality control plasma samples 
(0.75 µg/mL, 4.00 µg/mL and 8.00 µg/mL). Preparation 
of calibration standard plasma samples was accomplished 
daily by spiking drug-free plasma with known amounts 
of levofloxacin. Quality control plasma samples were 
prepared by adding known amounts of levofloxacin to 
drug-free plasma, aliquotation and storage at -20 °C. 
Specificity was investigated by analyzing four normal 
plasma samples, one hemolised plasma sample and one 
lipemic plasma sample for interference of endogenous 
compounds. The anticoagulant (heparin) interference was 
also verified during this stage. Recoveries of levofloxacin 
and IS were evaluated by comparing chromatographic 
peak areas from standard samples which did not undergo 
sample pre-treatment and from extracted plasma 
samples at quality control concentrations. The linearity 
was determined by the calibration curve ranging from 
0.25 µg/mL to 10.00 µg/mL, using least-squares linear 
regression analysis. The LLOQ was the smallest analytical 
concentration which could be measured with accuracy 
and precision still better than 20%. Intra- and inter-assay 
precision and accuracy were determined by repeated 
analysis of quality control plasma samples on the same 
day and on different days. Stability of levofloxacin in 
plasma was evaluated after three freezing-thaw cycles and 
after storage at -20 °C for 63 days. Additionally, stability 
of processed plasma samples during storage in the auto 
sampler for 24 and 48 hours at room temperature was 
determined.
Pharmacokinetic and statistical analysis
The following pharmacokinetic parameters were 
calculated using a non-compartmental model: Cmax, Tmax, 
AUC0-t (area under the plasma concentration-time curve 
from time zero to sample time of the last measurable 
levofloxacin concentration), AUC0-inf (area under the 
plasma concentration-time curve from time zero to infinity), 
Kel (elimination rate constant) and T1/2el (elimination 
half-life). Cmax and Tmax were obtained directly from the 
concentration-time curve. AUC0-t was calculated using the 
linear trapezoidal method. Kel was calculated by applying 
a log-linear regression analysis to at least the last three 
quantifiable concentrations of levofloxacin and T1/2el was 
calculated as 0.693/Kel (Dipiro et al., 1996). AUC0-inf was 
calculated as AUC0-t + Ct/Kel, where Ct is the last measurable 
levofloxacin concentration (Dipiro et al., 1996).
A sample size of 26 volunteers was chosen to 
evaluate bioequivalence with 80% power and to account 
for dropouts or withdrawals.
Analysis of variance (ANOVA) was performed on 
logarithmic transformed values of the pharmacokinetic 
parameters Cmax, AUC0-t and AUC0-inf. The ANOVA model 
included sequence, formulation, and period as fixed effects 
and subjects nested within sequence as random effect. 
These effects were tested at the 5% level of significance 
(Chow, Liu, 2000).
Bioequivalence between the products was 
determined by calculating 90% confidence intervals (90% 
CI) for the ratio of Cmax and AUC0-t values for the test and 
reference products, using logarithmic transformed data. 
The products were considered bioequivalent if the 90% 
CI for AUC0-t and Cmax fell within 80-125% (Agência 
Nacional de Vigilância Sanitária, 2006; European 
Medicines Agency, 2010; FDA, 2001).
RESULTS
Tolerability
A total of 26 healthy volunteers, 13 females and 13 
males, were included in the study after signing a consent 
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form. The mean (range) age, weight, and height of the 
subjects were 33 (21-43) years; 68 (49-86) kg; and 166 
(146–178) cm respectively. During the first period of the 
study, six volunteers from group A (reference product) and 
three from group B (test product) reported headache and 
one volunteer from group A reported nausea. During the 
second period, headache was reported by one volunteer 
from group A (test product) and two from group B 
(reference product) and nausea was reported by one 
volunteer from group B. No clinical abnormalities were 
found at the conclusion of the study.
Method validation and drug concentration in 
plasma
The HPLC method for levofloxacin quantification 
was specific for levofloxacin and IS, with total run time 
of 10 minutes, and was linear in the range of 0.25 µg/mL 
to 10.00 µg/mL. Intra and inter-assay accuracy ranged 
from 94.8% to 100.6%, and from 95.2% to 105.9%, 
respectively. Precision, measured as percent relative 
standard deviation (RSD%), was between 1.1% and 
1.8%, intra-assay, and between 1.9% and 6.3%, inter-
assay. Mean recovery was 83.3% for levofloxacin and 
86.4% for IS. The processed samples were stable at 
room temperature for at least 48 hours. Levofloxacin 
concentrations were not altered after three freeze-thaw 
cycles and plasma samples were stable for at least 63 
days when stored at -20 °C.
Average plasma concentrations of levofloxacin after 
administration of test and reference products to 26 healthy 
human volunteers are shown in Figure 1.
Pharmacokinetic parameters
The mean values for Cmax, Tmax, Kel, T1/2el, AUC0-t and 
AUC0-inf of the two products did not differ significantly, 
suggesting that plasma profiles generated by the test 
product are comparable to those produced by the reference 
TABLE I - Average (range) pharmacokinetic parameters after oral administration of reference (Tavanic®, Sanofi-Aventis Farmacêutica 
Ltda, Brazil) and test (Levaquin®, Janssen-Cilag Farmacêutica Ltda, Brazil) products to 26 healthy volunteers
Pharmacokinetic parameter Test Product Reference Product
Cmax (µg/mL) 5.67 (2.63-8.07) 5.69 (2.90-9.12)
Tmax (h) 1.29 (0.50-3.00) 1.60 (0.50-4.00)
Kel (h-1) 0.11 (0.07-0.19) 0.11 (0.07-0.16)
T1/2el (h) 6.69 (3.71-9.49) 6.55 (4.28-9.63)
AUC0-t (µg h/mL) 39.22 (23.84-52.89) 41.52 (26.53-56.60)
AUC0-inf (µg h/mL) 44.24 (27.64-57.26) 45.50 (31.03-61.98)
FIGURE 1 - Average plasma concentrations of levofloxacin 
after oral administration of reference (Tavanic®, Sanofi-Aventis 
Farmacêutica Ltda, Brazil) and test (Levaquin®, Janssen-Cilag 
Farmacêutica Ltda, Brazil) products to 26 healthy volunteers. 
Bars indicate mean standard errors (lower bars for reference 
product and upper bars for test product).
product. Pharmacokinetic parameters values are listed in 
Table I.
ANOVA detected the occurrence of period effect 
for Cmax, AUC0-t and AUC0-inf and product effect for AUC0-t 
(Table II). The 90% confidence intervals for the ratio of 
Cmax (92.1-108.2 %), AUC0-t (90.7-98.0 %) and AUC0-inf 
(94.8-100.0 %) values for test and reference products are 
within the 80-125% interval proposed by United States 
Food and Drug Administration (FDA) (2001), European 
Medicines Agency (EMEA) (2010) and Brazilian Agência 
Nacional de Vigilância Sanitária (ANVISA) (2006) 
(Table II). Power of statistic test was 0.99 for Cmax, 1.00 
for AUC0-t and 1.00 for AUC0-inf.
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DISCUSSION
Bioequivalence of drug products is usually 
assessed through open-label, randomized crossover 
studies (Eradiri et al., 2007; Howard et al., 2005; 
Schützer et al., 2004). End-points in bioequivalence trials 
(Cmax and AUC0-inf) are objective assessments, obtained 
from drug plasma concentration-time profiles. These 
assessments will not be affected by the knowledge of 
the treatment by the volunteer or the researcher. Since, 
in this case, it is not possible that unconscious bias will 
affect the observation, an open-label design can be used. 
In a crossover design, each subject serves as his or her 
own control, thus allowing a within subject comparison 
between formulations. It also removes the inter-subject 
variability from the comparison between formulations 
and, with a proper randomization of subjects to the 
sequence of formulation administrations, it provides 
the best unbiased estimates for the differences between 
formulations (Chow, Liu, 2000).
High-performance liquid chromatography (HPLC) 
methods with ultraviolet (UV) (Baietto et al., 2009; 
Chien et al., 1998; Djabarouti et al., 2004; Lee et al., 
1997; Liang, Kays, Sowinski, 2002; Nemutlu et al., 2007; 
Wong, Juzwin, Flor, 1997), fluorescence (Almeida et al., 
2005; Chien et al., 1997; Lubasch et al., 2000; Schulte et 
al., 2006; Siewert, 2006; Wagenlehner et al., 2006; Zhou 
et al., 2007) or mass spectrometry (Conte et al., 2006; 
Ji et al., 2006) detection for analysis of levofloxacin 
in biological fluids have been published. Sample 
preparation procedures include protein precipitation with 
acetonitrile, methanol, trifluoroacetic acid or perchloric 
acid (Baietto et al., 2009; Liang, Kays, Sowinski, 2002; 
Lubasch et al., 2000; Schulte et al., 2006; Siewert, 2006; 
Wagenlehner et al., 2006), liquid-liquid extraction (Chien 
et al., 1997, 1998; Lee et al., 1997;  Wong, Juzwin, 
Flor, 1997; Zhou et al., 2007), solid-phase extraction 
(Djabarouti et al., 2004; Nemutlu et al., 2007) and 
ultrafiltration (Liang, Kays, Sowinski, 2002). Most of 
the methods employ isocratic mobile phase, but the use 
of mobile phase gradient is also described (Baietto et al., 
2009; Nemutlu et al., 2007; Schulte et al., 2006; Siewert, 
2006). Although all of these methods are successful in 
the determination of levofloxacin, some of them have 
limitations including long chromatographic running time 
(Baietto et al., 2009; Siewert, 2006), and complicated 
and time-consuming sample pretreatment procedures 
(Chien et al., 1997).
The method used in this study has advantages 
when compared with others published methods: sample 
pre-treatment requires a one-step preparation, adding 
acetonitrile for protein precipitation; the chromatographic 
analysis was done in isocratic conditions; and the running 
time was 10 minutes for each sample.
The method showed good specificity, sensitivity, 
linearity, precision and accuracy over the entire 
concentration range achieved after oral administration 
of tablets conataining 500 mg of levofloxacin, thereby 
enabling its use in bioequivalence trials of this kind of 
formulations.
The average plasmatic decay curves obtained for the 
test product (Levaquin®) and reference product (Tavanic®) 
have the same pattern.
Levofloxacin was absorbed rapidly, achieving 
mean peak plasma level between 1 and 2 hours after drug 
administration for both test and reference products. Mean 
values for pharmacokinetic parameters Cmax (reference: 
5.69 µg/mL; test: 5.67 µg/mL), Tmax (reference: 1.60 h; 
test: 1.29 h), AUC0-t (reference: 41.52 µg·h/mL; test: 
39.22 µg·h/mL), AUC0-inf (reference: 45.50 µg·h/mL; 
test: 44.24 µg·h/mL) and T1/2el (reference: 6.55 hours; 
test: 6.69 hours) were similar to that reported by other 
authors (Amsden, Whitaker, Johnson, 2003; Chien 
et al., 1997; Lee et al., 1997; Lubasch et al., 2000; 
Wagenlehner et al., 2006). ANOVA revealed the absence 
of sequence effect for Cmax, AUC0-t e AUC0-inf. Period 
TABLE II - Analysis of variance (ANOVA) for the assessment of the product, sequence and period effects, and 90% confidence 
intervals (90% CI) for the ratio of Cmax, AUC0-t and AUC0-inf values for the test and reference products, using logarithmic transformed 
data, after oral administration of reference (Tavanic®, Sanofi-Aventis Farmacêutica Ltda, Brazil) and test (Levaquin®, Janssen-Cilag 
Farmacêutica Ltda, Brazil) products to 26 healthy volunteers (α=0.05)
Pharmacokinetic 
parameter
ANOVA (p value) 90% CI
Variation source
Product Sequence Period
Cmax 0.9696 0.5758 0.0217 92.1%-108.2 %
AUC0-t 0.0165 0.7999 0.0035 90.7%-98.0 %
AUC0-inf 0.0966 0.7604 0.0003 94.8%-100.0 %
Average bioequivalence of single 500 mg doses of two oral formulations of levofloxacin 209
effect was observed for Cmax, AUC0-t and AUC0-inf, and 
product effect was observed for AUC0-t. Regarding 
product effect, these finding does not mean that the 
formulations evaluated are not bioequivalent, since 
bioequivalence between two products is defined in terms 
of 90% CI. In this case, the occurrence of product effect 
indicates that there is a statistically significant difference 
between bioavailabilities of test and reference products 
regarding extension of drug absorption, but there is no 
difference regarding absorption rate, since no product 
effect was observed for Cmax. This difference in extension 
of drug absorption is not considered to be clinically 
important, since 90% CI is within the limits established 
by regulatory agencies (Pabst, Jaeger, 1990; Westlake, 
1979). A period effect measures the differences between 
study periods. A well-run study with consistent treatment 
of subjects should produce no significant period effects. 
However, a significant period effect does not invalidate 
the study, but the cause should be investigated (Ormsby, 
1994). Period effect may be due to a too short washout 
between periods (residual or carry-over effects), or they 
may reflect differing procedures of sample workup or 
storage, because for each subject usually all samples of 
all periods are analyzed within the same run. They also 
may be provoked by acclimatization or even weather 
conditions, or they may reflect an effect of the diet (Pabst, 
Jaeger, 1990). In the present study, predose samples 
did not exhibit any detectable levofloxacin level in all 
subjects, so the occurrence of residual or carry-over 
effects can be excluded. Also, procedures regarding 
volunteers’ diet and rest, drug administration and sample 
workup and storage were the same in the two periods 
of the study. On the basis of these considerations. the 
present bioequivalence study is acceptable, despite the 
period effect.
The 90% CI for the ratio of Cmax (92.1%-108.2 %), 
AUC0-t (90.7%-98.0 %) and AUC0-inf (94.8%-100.0 %) 
values for the test and reference products are within the 80-
125 % interval proposed by regulatory agencies, therefore 
test and reference products are bioequivalent according 
to average bioequivalence criteria, even if product effect 
have been detected in ANOVA.
CONCLUSIONS
Based on the pharmacokinetic and statistical results 
of this study, it was concluded that Tavanic© (Sanofi-Aventis 
Famacêutica Ltda, Brazil) and Levaquin© (Janssen-Cilag 
Farmacêutica Ltda, Brazil) are bioequivalent. Although a 
statistically significant difference between bioavailabilities 
of test and reference products regarding extension of 
drug absorption was detected trough ANOVA, this was 
not considered to be clinically important, since the 90% 
CI of the ratios for Cmax, AUC0-t and AUC0-inf were found 
to be within the regulatory agencies proposed acceptance 
limits (80-125%).
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